New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:16 EDTDEPO, MNKMallinckrodt receives patent from U.S. PTO
Mallinckrodt (MNK) announced that on July 29 the U.S. Patent and Trademark Office granted the company a new patent related to MNK-155. The patent, U.S. Patent Number 8,790,694 contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of MNK-155 and conveys the same period of exclusivity as did the patent granted in 2013 for the companyís product XARTEMIS XR Extended-Release Tablets. MNK-155 is Mallinckrodtís investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. The release profile of MNK-155 combines Mallinckrodt-proprietary technology and Depomedís (DEPO) advanced Acuform drug delivery technology.
News For MNK;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
07:57 EDTMNKMallinckrodt announces positive outcomes with H.P. Acthar gel in proteinuria
Subscribe for More Information
March 26, 2015
07:30 EDTMNKDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 23, 2015
13:23 EDTMNKLeerink pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry, discusses the strengths and weaknesses of INOmax's current patent portfolio, the likelihood Praxair's recently filed inter-partes review challenge succeeds on an Analyst/Industry conference call to be held on March 26 at 2 pm.
March 19, 2015
10:02 EDTDEPOOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:22 EDTDEPODepomed downgraded to Neutral at Janney Capital
Subscribe for More Information
08:16 EDTDEPODepomed downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information
March 17, 2015
08:35 EDTDEPODepomed announces expiration of waiting period to acquire rights of NUCYNTA
Depomed announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired with respect to Depomed's pending acquisition of U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals. The termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to completion of Depomed's previously announced financing and other customary closing conditions.
March 13, 2015
10:00 EDTDEPOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Aramark (ARMK) downgraded to Neutral from Outperform at RW Baird... Broadcom (BRCM) downgraded to Hold from Buy at Canaccord... Children's Place (PLCE) downgraded to Neutral from Buy at Citigroup... Depomed (DEPO) downgraded to Hold from Buy at WallachBeth... Diageo (DEO) downgraded to Underperform from Neutral at Credit Suisse... DreamWorks (DWA) downgraded to Neutral from Buy at B. Riley... Gaming and Leisure Properties (GLPI) downgraded to Neutral at Susquehanna... Genesco (GCO) downgraded at Sterne Agee... Host Hotels (HST) downgraded to Underperform from Market Perform at Raymond James... InspireMD (NSPR) downgraded at Oppenheimer... Integrated Silicon (ISSI) downgraded to Neutral from Buy at B. Riley... InterXion (INXN) downgraded to Market Perform from Outperform at Raymond James... JG Wentworth (JGW) downgraded to Hold from Buy at Jefferies... Lumber Liquidators (LL) downgraded to Neutral from Buy at Goldman... QIWI (QIWI) downgraded to Neutral at Susquehanna... Regional Management (RM) downgraded to Underperform from Neutral at Macquarie... Royal Dutch Shell (RDS.A) downgraded to Sector Perform from Outperform at RBC Capital... Rudolph Technologies (RTEC) downgraded to Neutral from Buy at DA Davidson.
07:10 EDTDEPODepomed downgraded to Hold from Buy at WallachBeth
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use